company background image
FLGT

Fulgent GeneticsNasdaqGM:FLGT Stock Report

Last Price

US$60.70

Market Cap

US$1.8b

7D

-24.1%

1Y

-12.3%

Updated

21 Jan, 2022

Data

Company Financials +
FLGT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance6/6
Financial Health5/6
Dividends0/6

FLGT Stock Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information.

Fulgent Genetics Competitors

Guardant Health

NasdaqGS:GH

US$7.1b

Progenity

NasdaqGM:PROG

US$221.8m

PerkinElmer

NYSE:PKI

US$22.1b

Natera

NasdaqGS:NTRA

US$5.9b

Price History & Performance

Summary of all time highs, changes and price drops for Fulgent Genetics
Historical stock prices
Current Share PriceUS$60.70
52 Week HighUS$189.89
52 Week LowUS$60.59
Beta1.34
1 Month Change-41.72%
3 Month Change-27.79%
1 Year Change-12.33%
3 Year Change1,321.55%
5 Year Change366.92%
Change since IPO561.22%

Recent News & Updates

Jan 09

Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy

I was bearish on Fulgent in 2021, expecting the stock to slump as Covid-19 testing revenues faded. Delta and omicron have extended the window for testing dramatically. Even so, Fulgent stock has underwhelmed in recent months. The company's business has improved enough to mitigate much of the bearish case, however I'm still no more than neutral on the stock.

Dec 20

Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot

Fulgent's COVID testing business isn't going away any time soon and will continue to gush cash for reinvestment, even allowing for melting ice cube scenarios. Fulgent's core business continues to grow at a high rate and has benefited from COVID testing related capitalization. Fulgent, with its brilliant founder, strong insider ownership, plummeting EV, and high growth core business, is undervalued.

Shareholder Returns

FLGTUS HealthcareUS Market
7D-24.1%-3.5%-6.1%
1Y-12.3%12.7%4.2%

Return vs Industry: FLGT underperformed the US Healthcare industry which returned 12.8% over the past year.

Return vs Market: FLGT underperformed the US Market which returned 6.6% over the past year.

Price Volatility

Is FLGT's price volatile compared to industry and market?
FLGT volatility
FLGT Average Weekly Movement9.8%
Healthcare Industry Average Movement7.9%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: FLGT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: FLGT's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011626Ming Hsiehhttps://www.fulgentgenetics.com

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions.

Fulgent Genetics Fundamentals Summary

How do Fulgent Genetics's earnings and revenue compare to its market cap?
FLGT fundamental statistics
Market CapUS$1.81b
Earnings (TTM)US$569.33m
Revenue (TTM)US$1.04b

3.2x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FLGT income statement (TTM)
RevenueUS$1.04b
Cost of RevenueUS$205.17m
Gross ProfitUS$830.72m
ExpensesUS$261.39m
EarningsUS$569.33m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)19.08
Gross Margin80.19%
Net Profit Margin54.96%
Debt/Equity Ratio2.0%

How did FLGT perform over the long term?

See historical performance and comparison

Valuation

Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FLGT ($60.7) is trading below our estimate of fair value ($5863.67)

Significantly Below Fair Value: FLGT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FLGT is good value based on its PE Ratio (3.2x) compared to the US Healthcare industry average (20.3x).

PE vs Market: FLGT is good value based on its PE Ratio (3.2x) compared to the US market (16.7x).


Price to Earnings Growth Ratio

PEG Ratio: FLGT's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: FLGT is good value based on its PB Ratio (1.7x) compared to the US Healthcare industry average (2.6x).


Future Growth

How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-69.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLGT's earnings are forecast to decline over the next 3 years (-69.3% per year).

Earnings vs Market: FLGT's earnings are forecast to decline over the next 3 years (-69.3% per year).

High Growth Earnings: FLGT's earnings are forecast to decline over the next 3 years.

Revenue vs Market: FLGT's revenue is expected to decline over the next 3 years (-40.6% per year).

High Growth Revenue: FLGT's revenue is forecast to decline over the next 3 years (-40.6% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FLGT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Fulgent Genetics performed over the past 5 years?

94.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FLGT has high quality earnings.

Growing Profit Margin: FLGT's current net profit margins (55%) are higher than last year (35.3%).


Past Earnings Growth Analysis

Earnings Trend: FLGT has become profitable over the past 5 years, growing earnings by 94% per year.

Accelerating Growth: FLGT's earnings growth over the past year (1093.4%) exceeds its 5-year average (94% per year).

Earnings vs Industry: FLGT earnings growth over the past year (1093.4%) exceeded the Healthcare industry 32.5%.


Return on Equity

High ROE: FLGT's Return on Equity (54.5%) is considered outstanding.


Financial Health

How is Fulgent Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: FLGT's short term assets ($622.8M) exceed its short term liabilities ($147.2M).

Long Term Liabilities: FLGT's short term assets ($622.8M) exceed its long term liabilities ($13.1M).


Debt to Equity History and Analysis

Debt Level: FLGT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if FLGT's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: FLGT's debt is well covered by operating cash flow (2829.6%).

Interest Coverage: FLGT earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Fulgent Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Ming Hsieh (65 yo)

5.67yrs

Tenure

US$248,000

Compensation

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and serve...


CEO Compensation Analysis

Compensation vs Market: Ming's total compensation ($USD248.00K) is below average for companies of similar size in the US market ($USD3.73M).

Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: FLGT's management team is considered experienced (4.5 years average tenure).


Board Members

Experienced Board: FLGT's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: FLGT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.9%.


Top Shareholders

Company Information

Fulgent Genetics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Fulgent Genetics, Inc.
  • Ticker: FLGT
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$1.811b
  • Shares outstanding: 29.83m
  • Website: https://www.fulgentgenetics.com

Number of Employees


Location

  • Fulgent Genetics, Inc.
  • 4978 Santa Anita Avenue
  • Temple City
  • California
  • 91780
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:55
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.